$SGNT (Sagent Pharmaceuticals, Inc.)

$SGNT {{ '2016-07-11T16:00:18+0000' | timeago}} • Announcement

$SGNT said JPMorgan Securities Japan Co. Ltd. acted as financial advisor, and Nishimura & Asahi, Paul, Weiss, Rifkind, Wharton & Garrison LLP, & Hyman, Phelps & McNamara, PC acted as legal counsel to Nichi-Iko. Perella Weinberg Partners and Morgan Stanley & Co. LLC acted as financial advisors, & Kirkland & Ellis LLP acted as legal counsel to $SGNT.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$VRTX {{ '2017-07-13T12:31:35+0000' | timeago}} • Announcement

$VRTX announced that the Italian Medicines Agency has agreed to reimburse ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. Effective immediately, hundreds of eligible patients in Italy will have access to this medicine.

$PFE {{ '2017-07-13T12:13:49+0000' | timeago}} • Announcement

The FDA has accepted $PFE's filing of supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis. The FDA has provided an anticipated Prescription Drug User Fee Act action date in March 2018 for the sNDA.

$PFE {{ '2017-07-12T11:41:14+0000' | timeago}} • Announcement

$PFE said the FDA's Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk benefit profile for Mylotarg on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

$PFE {{ '2017-07-11T20:58:23+0000' | timeago}} • Announcement

The US FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of $PFE's MYLOTARG (gemtuzumab ozogamicin), an antibody-drug conjugate used to treat acute myeloid leukemia. The role of the ODAC is to provide recommendations to the FDA. The FDA decision on whether or not to approve MYLOTARG is anticipated by Sept. 2017.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$PFE {{ '2017-06-30T12:36:12+0000' | timeago}} • Announcement

$PFE received approval for its Besponsa as monotherapy from the European Commission. The Besponsa was approved for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). ALL is an aggressive type of leukemia that can be fatal within a matter of months if left untreated.

$ACOR {{ '2017-06-29T20:59:19+0000' | timeago}} • Announcement

$ACOR submits New Drug Application (NDA) to FDA for Inbrija, a potential therapy for patients with Parkinson’s disease. Acorda Therapeutics plans to file a Marketing Authorization Application (MAA) in Europe for Inbrija by the end of 2017.

$PFE {{ '2017-06-27T13:34:31+0000' | timeago}} • Announcement

$PFE broke ground on its new R&D and process development facility in Chesterfield, Missouri. Construction is expected to be complete by mid-2019. The facility will house more than 450 employees who currently work at multiple locations, and an additional 80 employees that the company expects to hire over the coming years.

$PFE {{ '2017-06-22T20:52:12+0000' | timeago}} • Announcement

$PFE declared a $0.32 3Q17 dividend on the company’s common stock, payable September 1, 2017, to shareholders of record as on August 4, 2017.

$REGN {{ '2017-06-22T14:02:42+0000' | timeago}} • Announcement

$REGN provided details of the royalty it receives on any sales of canakinumab (ACZ885). $REGN received a royalty on worldwide net sales of canakinumab; the royalty rate starts at 4% and reaches 15% when canakinumab annual sales exceed $1.5Bil.

$AVP {{ '2017-06-21T15:49:35+0000' | timeago}} • Announcement

$AVP said Fernando Acosta, EVP and Chief Marketing and Social Selling Officer, has decided not to relocate to the UK and will therefore be leaving the company, Nov. 1, 2017. James Scully, current EVP and COO, will be leaving the company Oct. 1 2017, following his previously announced decision not to relocate to London.

$AVP {{ '2017-06-21T15:48:06+0000' | timeago}} • Announcement

$AVP appointed Jonathan Myers as EVP and COO, effective Sept. 1, 2017. Most recently, Jonathan served as $K's VP, Western European Markets, and Managing Director, UK and Ireland. Last week, $AVP appointed Miguel Fernandez as Global President responsible for Commercial Business Operations.

$AVP {{ '2017-06-21T15:26:42+0000' | timeago}} • Announcement

$AVP appointed Miguel Fernandez as Global President, with responsibility for commercial business operations, effective Aug. 14, 2017. Miguel succeeds John Higson, who will be retiring in September from his role as $AVP's EVP, Chief Commercial Officer, following 32 years with the company.

$ACET {{ '2017-06-20T14:58:15+0000' | timeago}} • Announcement

$ACET said its finished dosage form generics subsidiary Rising Pharmaceuticals has launched Glipizide Extended Release Tablets, an FDA-approved generic version of the reference listed drug, Glucotrol XL from $PFE. Glipizide are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

$ACET {{ '2017-06-20T14:56:43+0000' | timeago}} • Announcement

$ACET said its finished dosage form generics subsidiary Rising Pharmaceuticals has launched an FDA-approved generic version of Chlorthalidone Tablets, 25 mg and 50 mg, which are indicated for the management of hypertension.

$PFE {{ '2017-06-19T13:59:58+0000' | timeago}} • Announcement

$PFE started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection. In newborns, GBS manifests as sepsis, pneumonia, and meningitis, with potentially fatal outcomes for some, and long-lasting neurological damage in 46-50% of those infected.

$ZTS {{ '2017-06-16T17:01:44+0000' | timeago}} • Announcement

Nexvet Biopharma, $ZTS, and Zoetis Belgium jointly dispatched a letter to the holders of convertible securities of Nexvet in accordance with Rule 15 of the Irish Takeover Rules to provide information regarding how the Acquisition of Nexvet by $ZTS will affect such securities.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
ACET (Aceto Corp.)
Friday, May 5 2017 - 1:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
AVP (Avon Products Inc.)
Thursday, May 4 2017 - 1:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
CBM (Cambrex Corporation.)
Thursday, May 4 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, April 27 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, April 26 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
MDCO (The Medicines Company)
Tuesday, February 28 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, February 28 2017 - 1:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, February 23 2017 - 9:30pm

AlphaGraphics you may like